Cancer Genetics Reports Q2 Financial Results

- August 20th, 2019

Cancer Genetics (NASDAQ:CGIX) has released its second quarter results for the quarter ended June 30, 2019. As quoted in the press release: RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS Completed divestiture of two operating units for cash, notes and future payment streams Consolidated operational focus on drug discovery and preclinical service business of vivoPharm Increased Discovery Services … Continued

Cancer Genetics (NASDAQ:CGIX) has released its second quarter results for the quarter ended June 30, 2019.

As quoted in the press release:

RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS

  • Completed divestiture of two operating units for cash, notes and future payment streams
  • Consolidated operational focus on drug discovery and preclinical service business of vivoPharm
  • Increased Discovery Services revenue in Q2 2019 by 19.1%, compared to same period of 2018
  • Continuing to explore strategic alternatives for future sale of other assets, merger, reverse merger or other strategic transactions

“We are very pleased with the progress we have made in improving the Company’s financial condition through the divestiture of certain corporate assets, giving the Company time to explore a variety of new strategic alternatives,” said John A. Roberts, Chief Executive Officer of Cancer Genetics. “Also, during the second quarter, we delivered an increase in revenue growth of 19.1% from our remaining Discovery Services business unit, while reducing the combined quarterly cost of revenue from continuing operations by $0.4 million.”

Click here to read the full press release.

The newest developments in genetics investing

 
Find out what to watch for in the world of genetics

One response to “Cancer Genetics Reports Q2 Financial Results

  1. Yesterday close was 9,2 cents, investors are losing everything. The SEC should prevent those companies, which are not serious, to be listed in public stockmarkets such as Nasdaq and NYSE.. OTC Pink Sheets is the only proper listing vehicle. A serious company should be committed to keep own stock price to reasonable levels for investors benefit. CGIX looks like a scam, unfortunately it not the only case.

Leave a Reply

Your email address will not be published. Required fields are marked *